Skip to content
Menu

Assembly Biosciences, Inc. ASMB

Full chart Compare
Set alert

Price alert · ASMB

All alert types
22.15 USD -0.35 (-1.54%)

As ofNov 20, 2026, 12:46 PM EST

22.04 Day range 22.21
19.20 52-week range 39.65
YTD
-34.86%
1 year
-39.69%

5D +2.49 (+12.44%)

2022FriMonTueWedThu22.50
Market cap
454.80M
Revenue (ttm)
21.48M
Profit margin
-212.33%
EPS (ttm)
0.75
Shares out
6.36M
P/E ratio
29.61
Forward P/E
-2.12
YTD return
-34.86%
1-year return
-39.69%
Volume
191.58K
Avg volume
307.20K
Open
22.20
Previous close
22.50
Day's range
22.04 – 22.21
52-week range
19.20 – 39.65
Beta
0.59
Price target
35.50 (+60.3%)
50-day average
16.31

Key statistics

200-day average
15.02
Enterprise value
3.57M
Price / sales
4.36
Price / book
1.96
Free cash flow
5.50M
Total cash
109.22M
Total debt
1.75M
Return on equity
-101.77%
Short % of float
0.38%

Fundamental scorecard

7 of 25 checks passed on ASMB’s reported financials

ValueGrowthProfitabilityHealthDividend

7of 25 checks passed

  • Value 1 of 5
  • Growth 2 of 5
  • Profitability 1 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
ASMB Revenue — quarterly 2.96M
ASMB Net income — quarterly -20.26M
ASMB EPS — quarterly -0.93

Earnings

ASMB recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 7, 2024Sep 1, 2024-2.02-1.51+0.51+25.25%
Aug 8, 2024Jun 1, 2024-2.96-1.98+0.98+33.11%
May 8, 2024Mar 1, 2024-2.74-1.66+1.08+39.42%
Mar 27, 2024Dec 1, 2023-2.88———
Nov 8, 2023Sep 1, 2023-2.76-3.24-0.48-17.39%
Aug 9, 2023Jun 1, 2023-3.48-3.84-0.36-10.34%

Upgrades / downgrades

ASMB analyst upgrades and downgrades
DateFirmActionFromTo
Jun 20, 2024HC Wainwright & Co.reit—Neutral
Jun 13, 2024HC Wainwright & Co.reit—Neutral
Apr 1, 2024HC Wainwright & Co.reit—Neutral

About Assembly Biosciences, Inc.

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on ASMB — it syncs with the Stock Master app.

Insider holders

ASMB insider holders
InsiderRelationLatest transactionDateShares held
BJORKQUIST JEANETTE MOfficerSaleMay 22, 20243,142
DELANEY WILLIAM E IVOfficerStock Award(Grant)Apr 28, 202416,109
GILEAD SCIENCES INCBeneficial Owner of more than 10% of a Class of SecurityPurchaseJun 16, 20241,268,970
MCHUTCHISON JOHN GDirectorSaleMay 22, 202419,104
OKAZAKI JASON AChief Executive OfficerSaleOct 2, 202414,904
SCHORNSTEIN ALEXANDERBeneficial Owner of more than 10% of a Class of SecurityPurchaseNov 24, 2024728,113

Institution ownership

ASMB institution ownership
Holder% heldSharesValueReported
Armistice Capital, LLC5.57%354,0005.21MSep 29, 2024
Vanguard Group Inc3.15%200,4582.95MSep 29, 2024
Blackrock Inc.1.21%77,1081.14MSep 29, 2024
Renaissance Technologies, LLC1.03%65,624965.99KSep 29, 2024
Acuitas Investments LLC0.98%62,315917.28KSep 29, 2024
Geode Capital Management, LLC0.74%47,034692.34KSep 29, 2024

Fund ownership

ASMB fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund1.81%114,7821.69MSep 29, 2024
Vanguard Extended Market Index Fund1.04%66,356976.76KSep 29, 2024
Federated Hermes MDT Mid Cap Growth Fund0.40%25,394373.80KOct 30, 2024
Fidelity Extended Market Index Fund0.37%23,660348.27KOct 30, 2024
Vanguard Horizon Fund-Strategic Small-Cap Equity Fund0.28%17,723260.88KSep 29, 2024
Bridgeway Funds Inc-Ultra Small Company Market Fund0.22%13,750202.40KSep 29, 2024